002821 凯莱英
已收盘 09-19 15:00:00
资讯
新帖
简况
凯莱英(06821)股价上升6.643%，现价港币$44.95
阿斯达克财经 · 11:15
凯莱英(06821)股价上升6.643%，现价港币$44.95
凯莱英：9月13日高管徐向科、周炎增持股份合计6500股
证券之星 · 09-18 21:01
凯莱英：9月13日高管徐向科、周炎增持股份合计6500股
挪威中央银行增持凯莱英(06821)13.09万股 每股作价约38.85港元
智通财经 · 09-16 19:19
挪威中央银行增持凯莱英(06821)13.09万股 每股作价约38.85港元
凯莱英(06821)下跌5.2%，报41.9元/股
金融界 · 09-16
凯莱英(06821)下跌5.2%，报41.9元/股
凯莱英(06821)股价下跌5.204%，现价港币$41.9
阿斯达克财经 · 09-16
凯莱英(06821)股价下跌5.204%，现价港币$41.9
凯莱英：9月12日高管张达增持股份合计7.4万股
证券之星 · 09-13
凯莱英：9月12日高管张达增持股份合计7.4万股
凯莱英：公司2024年回购计划尚未披露回购完成公告，相关事项具体进展请以公司后续披露的公告为准
证券之星 · 09-13
凯莱英：公司2024年回购计划尚未披露回购完成公告，相关事项具体进展请以公司后续披露的公告为准
凯莱英(06821)上涨5.2%，报42.5元/股
金融界 · 09-12
凯莱英(06821)上涨5.2%，报42.5元/股
A股医药股震荡走高，康芝药业涨停，阳普医疗涨超15%，海南海药、济民健康涨停，普利制药、药明康德、凯莱英等跟涨。
美港电讯 · 09-12
A股医药股震荡走高，康芝药业涨停，阳普医疗涨超15%，海南海药、济民健康涨停，普利制药、药明康德、凯莱英等跟涨。
凯莱英(06821.HK)董事及高管拟增持A股 规模不低于2,000万人民币
阿斯达克财经 · 09-11
凯莱英(06821.HK)董事及高管拟增持A股 规模不低于2,000万人民币
凯莱英最新公告：部分董事、高级管理人员等拟不低于2000万元增持公司A股股份
证券之星 · 09-11
凯莱英最新公告：部分董事、高级管理人员等拟不低于2000万元增持公司A股股份
凯莱英(06821)部分董事、高级管理人员和核心技术及业务人员拟增持不低于2000万元公司A股股份
智通财经 · 09-11
凯莱英(06821)部分董事、高级管理人员和核心技术及业务人员拟增持不低于2000万元公司A股股份
凯莱英：部分董事高管拟增持不低于2000万元A股
美港电讯 · 09-11
凯莱英：部分董事高管拟增持不低于2000万元A股
凯莱英（002821）9月10日主力资金净买入478.46万元
证券之星 · 09-11
凯莱英（002821）9月10日主力资金净买入478.46万元
凯莱英(06821)截至8月末累计回购公司A股股份数量为1230.07万股
智通财经网 · 09-02
凯莱英(06821)截至8月末累计回购公司A股股份数量为1230.07万股
凯莱英(002821.SZ)已累计回购3.5976%股份 耗资约10亿元
智通财经 · 09-02
凯莱英(002821.SZ)已累计回购3.5976%股份 耗资约10亿元
中邮证券：给予凯莱英买入评级
证券之星 · 09-02
中邮证券：给予凯莱英买入评级
凯莱英：计划参加2024年度天津辖区上市公司半年报业绩说明会暨投资者网上集体接待日活动
金融界港股 · 08-30
凯莱英：计划参加2024年度天津辖区上市公司半年报业绩说明会暨投资者网上集体接待日活动
凯莱英（002821）2024年中报简析：净利润减70.4%，三费占比上升明显
证券之星 · 08-30
凯莱英（002821）2024年中报简析：净利润减70.4%，三费占比上升明显
民生证券：给予凯莱英买入评级
证券之星 · 08-30
民生证券：给予凯莱英买入评级
加载更多
公司概况
公司名称：
凯莱英医药集团(天津)股份有限公司
所属行业：
医药制造业
上市日期：
2016-11-18
主营业务：
凯莱英医药集团(天津)股份有限公司是一家全球领先的服务于新药研发和生产的CDMO一站式综合服务商。为国内外大中型制药企业、生物技术公司提供高效和高质量的研发与生产服务，助推创新药的临床研究与商业化应用。主要包括临床阶段药品、商业化阶段药品、技术服务。公司是全球第五大创新药原料药CDMO公司，约占据1.5%的市场份额（第一名市场份额约为2.9%）；是中国最大的商业化阶段化学药物CDMO公司，约占据22%的市场份额。
发行价格：
30.53
{"stockData":{"symbol":"002821","market":"SZ","secType":"STK","nameCN":"凯莱英","latestPrice":64.41,"timestamp":1726729380000,"preClose":62.77,"halted":0,"volume":3905826,"delay":0,"floatShares":329000000,"shares":368000000,"eps":2.9414,"marketStatus":"已收盘","marketStatusCode":5,"change":1.64,"latestTime":"09-19 15:00:00","open":63.21,"high":65,"low":62.05,"amount":250000000,"amplitude":0.047,"askPrice":64.42,"askSize":9,"bidPrice":64.41,"bidSize":49,"shortable":0,"etf":0,"ttmEps":2.9414,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1726795800000},"adr":0,"adjPreClose":62.77,"symbolType":"stock","openAndCloseTimeList":[[1726709400000,1726716600000],[1726722000000,1726729200000]],"highLimit":69.05,"lowLimit":56.49,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":367718103,"pbRate":1.4,"roa":"--","roe":"2.87%","epsLYR":6.26,"committee":0.761905,"marketValue":23685000000,"floatMarketCap":21169000000,"peRate":21.897735,"changeRate":0.0261,"turnoverRate":0.0119,"status":0},"requestUrl":"/m/hq/s/002821","defaultTab":"news","newsList":[{"id":"2468181145","title":"凯莱英(06821)股价上升6.643%，现价港币$44.95","url":"https://stock-news.laohu8.com/highlight/detail?id=2468181145","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468181145?lang=zh_cn&edition=full","pubTime":"2024-09-19 11:15","pubTimestamp":1726715700,"startTime":"0","endTime":"0","summary":"[上升股]凯莱英(06821) 股价在上午11:15比前收市价上升6.643%，现股价为港币$44.95。至目前为止，今日最高价为$45.0，而最低价为$42.2。总成交量为17.6万股，总成交金额为港币$768.926万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2409192604/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["002821","BK0132","BK1191","LU1328615791.USD","BK0239","06821"],"gpt_icon":0},{"id":"2468898705","title":"凯莱英：9月13日高管徐向科、周炎增持股份合计6500股","url":"https://stock-news.laohu8.com/highlight/detail?id=2468898705","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468898705?lang=zh_cn&edition=full","pubTime":"2024-09-18 21:01","pubTimestamp":1726664460,"startTime":"0","endTime":"0","summary":"证券之星消息，根据9月18日市场公开信息、上市公司公告及交易所披露数据整理，凯莱英最新董监高及相关人员股份变动情况：2024年9月13日公司董秘,高管徐向科、高管周炎共增持公司股份6500.0股，占公司总股本为0.0018%。变动期间公司股价上涨0.47%，9月13日当日收盘报63.88元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024091800030851.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","002821","LU1328615791.USD","BK1191","06821","BK0239"],"gpt_icon":0},{"id":"2467147948","title":"挪威中央银行增持凯莱英(06821)13.09万股 每股作价约38.85港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2467147948","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467147948?lang=zh_cn&edition=full","pubTime":"2024-09-16 19:19","pubTimestamp":1726485595,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，9月10日，挪威中央银行增持凯莱英(06821)13.09万股，平均每股作价为38.8452港元，总金额约为508.48万港元。增持后最新持股数目为169.71万股，最新持股比例为6.16%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1183636.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06821","BK0239","BK1191","BK0132","002821","LU1328615791.USD"],"gpt_icon":0},{"id":"2467862293","title":"凯莱英(06821)下跌5.2%，报41.9元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2467862293","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467862293?lang=zh_cn&edition=full","pubTime":"2024-09-16 13:23","pubTimestamp":1726464184,"startTime":"0","endTime":"0","summary":"9月16日，凯莱英(06821)盘中下跌5.2%，截至13:23，报41.9元/股，成交106.09万元。凯莱英医药集团是一家全球领先的CDMO公司，主要为全球新药提供从临床早期到商业化阶段的一站式研发、生产服务，包括高级中间体、原料药、制剂的研发和cGMP生产，以及临床研究服务。公司通过持续技术创新和战略合作，为国内外制药公司、生物技术公司提供药品全生命周期一站式CMC服务，加快新药开发及应用，逐步构建起创新药一体化服务生态圈。截至2024年中报，凯莱英营业总收入26.55亿元、净利润4.99亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/09/16132343306307.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","BK0132","BK1191","LU1328615791.USD","002821","06821"],"gpt_icon":0},{"id":"2467686271","title":"凯莱英(06821)股价下跌5.204%，现价港币$41.9","url":"https://stock-news.laohu8.com/highlight/detail?id=2467686271","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467686271?lang=zh_cn&edition=full","pubTime":"2024-09-16 13:15","pubTimestamp":1726463700,"startTime":"0","endTime":"0","summary":"[下跌股]凯莱英(06821) 股价在下午01:15比前收市价下跌5.204%，现股价为港币$41.9。至目前为止，今日最高价为$44.6，而最低价为$41.9。总成交量为1.56万股，总成交金额为港币$66.94万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152742524_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152742524_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2409161125/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["002821","BK0132","LU1328615791.USD","BK1191","BK0239","06821"],"gpt_icon":0},{"id":"2467772060","title":"凯莱英：9月12日高管张达增持股份合计7.4万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2467772060","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467772060?lang=zh_cn&edition=full","pubTime":"2024-09-13 21:01","pubTimestamp":1726232473,"startTime":"0","endTime":"0","summary":"证券之星消息，根据9月13日市场公开信息、上市公司公告及交易所披露数据整理，凯莱英最新董监高及相关人员股份变动情况：2024年9月12日公司董事,高管张达共增持公司股份7.4万股，占公司总股本为0.0201%。变动期间公司股价上涨1.47%，9月12日当日收盘报63.58元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024091300041748.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1328615791.USD","BK0132","002821","BK0239","06821","BK1191"],"gpt_icon":0},{"id":"2467274470","title":"凯莱英：公司2024年回购计划尚未披露回购完成公告，相关事项具体进展请以公司后续披露的公告为准","url":"https://stock-news.laohu8.com/highlight/detail?id=2467274470","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467274470?lang=zh_cn&edition=full","pubTime":"2024-09-13 18:03","pubTimestamp":1726221813,"startTime":"0","endTime":"0","summary":"证券之星消息，凯莱英09月13日在投资者关系平台上答复投资者关心的问题。公司2024年回购计划尚未披露回购完成公告，相关事项具体进展请以公司后续披露的公告为准。另外，公司已于2024年9月12日在巨潮资讯网披露《关于部分董事、高级管理人员和核心技术人员增持公司A股股份计划的公告》。详情请查阅公司公告，感谢您的关注！以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024091300032138.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1328615791.USD","BK0239","BK0132","06821","002821","BK1191"],"gpt_icon":0},{"id":"2466217062","title":"凯莱英(06821)上涨5.2%，报42.5元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2466217062","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466217062?lang=zh_cn&edition=full","pubTime":"2024-09-12 13:21","pubTimestamp":1726118504,"startTime":"0","endTime":"0","summary":"9月12日，凯莱英(06821)盘中上涨5.2%，截至13:21，报42.5元/股，成交932.06万元。凯莱英医药集团是一家全球领先的CDMO公司，主要为全球新药提供从临床早期到商业化阶段的一站式研发、生产服务，包括高级中间体、原料药、制剂的研发和cGMP生产，以及临床研究服务。公司通过持续技术创新和战略合作，为国内外制药公司、生物技术公司提供药品全生命周期一站式CMC服务，加快新药开发及应用，逐步构建起创新药一体化服务生态圈。截至2024年中报，凯莱英营业总收入26.55亿元、净利润4.99亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/09/12132143203014.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU1328615791.USD","BK0239","BK0132","06821","002821","BK1191"],"gpt_icon":0},{"id":"2466929450","title":"A股医药股震荡走高，康芝药业涨停，阳普医疗涨超15%，海南海药、济民健康涨停，普利制药、药明康德、凯莱英等跟涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2466929450","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466929450?lang=zh_cn&edition=full","pubTime":"2024-09-12 09:49","pubTimestamp":1726105741,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU1046422090.SGD","159938","159982","06821","BK0132","LU2242644610.SGD","BK1141","300630","BK0060","BK0188","BK1574","BK1576","LU1328615791.USD","300030","LU0708995583.HKD","300086","603222","BK1583","BK0070","BK0239","399300","LU0052750758.USD","LU0456842615.SGD","02359","BK0048","002821","09939","LU2125910500.SGD","BK0146","LU1997245177.USD","LU2045819591.USD","BK0216","000566","BK1191","BK1161","LU2488822045.USD","BK0042","603259","LU0320764599.SGD","BK0201","BK0251","LU1997245094.SGD","BK0028","BK1515"],"gpt_icon":0},{"id":"2466282531","title":"凯莱英(06821.HK)董事及高管拟增持A股 规模不低于2,000万人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2466282531","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466282531?lang=zh_cn&edition=full","pubTime":"2024-09-11 21:38","pubTimestamp":1726061880,"startTime":"0","endTime":"0","summary":"凯莱英(06821.HK) 公布，董事张达、洪亮、张婷，高级管理人员姜英伟、陈朝勇、周炎、徐向科及部分核心技术及业务人员计划即日起六个月内，以集中竞价方式增持公司A股股份，规模不低于2,000万人民币。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-09-11 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20211130083534767_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20211130083534767_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1380740/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["159982","BK0132","LU1328615791.USD","BK1191","002821","399300","06821","BK0239"],"gpt_icon":0},{"id":"2466060784","title":"凯莱英最新公告：部分董事、高级管理人员等拟不低于2000万元增持公司A股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2466060784","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466060784?lang=zh_cn&edition=full","pubTime":"2024-09-11 18:20","pubTimestamp":1726050057,"startTime":"0","endTime":"0","summary":"凯莱英公告，公司部分董事、高级管理人员和核心技术及业务人员计划以集中竞价交易的方式增持公司A股股份，增持主体拟合计增持金额不低于2000万元（含）。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024091100032614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","LU1328615791.USD","159982","399300","002821","06821","BK0132","BK0239"],"gpt_icon":0},{"id":"2466406722","title":"凯莱英(06821)部分董事、高级管理人员和核心技术及业务人员拟增持不低于2000万元公司A股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2466406722","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466406722?lang=zh_cn&edition=full","pubTime":"2024-09-11 18:20","pubTimestamp":1726050027,"startTime":"0","endTime":"0","summary":"本次增持不设置固定价格、价格区间，增持主体将根据公司股票价格波动情况及资本市场整体趋势择机实施增持计划。具体增持数量以增持期满时实际增持的股份数量为准。拟增持股份的规模：不低于人民币2000万元。实施期限：自本公告披露之日起6个月内。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1182054.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159982","BK0132","002821","399300","LU1328615791.USD","06821","BK0239","BK1191"],"gpt_icon":0},{"id":"2466657406","title":"凯莱英：部分董事高管拟增持不低于2000万元A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2466657406","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466657406?lang=zh_cn&edition=full","pubTime":"2024-09-11 18:13","pubTimestamp":1726049592,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0239","BK0132","LU1328615791.USD","06821","399001","399300","002821","159982","BK1191"],"gpt_icon":0},{"id":"2466443868","title":"凯莱英（002821）9月10日主力资金净买入478.46万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2466443868","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466443868?lang=zh_cn&edition=full","pubTime":"2024-09-11 09:24","pubTimestamp":1726017893,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年9月10日收盘，凯莱英报收于61.05元，下跌1.58%，换手率0.84%，成交量2.76万手，成交额1.69亿元。近5日资金流向一览见下表：凯莱英融资融券信息显示，融资方面，当日融资买入970.41万元，融资偿还1341.22万元，融资净偿还370.81万元。凯莱英主营业务：是一家全球领先、技术驱动型的医药外包服务一站式综合服务商。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024091100009327.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1328615791.USD","BK0239","BK0132","06821","002821","BK1191"],"gpt_icon":0},{"id":"2464889458","title":"凯莱英(06821)截至8月末累计回购公司A股股份数量为1230.07万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2464889458","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464889458?lang=zh_cn&edition=full","pubTime":"2024-09-02 17:31","pubTimestamp":1725269511,"startTime":"0","endTime":"0","summary":"凯莱英(06821)发布公告，截至2024年8月30日，公司累计通过回购专用证券账...","market":"us","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_1.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_1.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1178098.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0132","159982","002821","399300","LU1328615791.USD","BK1191","06821","BK0239"],"gpt_icon":0},{"id":"2464869988","title":"凯莱英(002821.SZ)已累计回购3.5976%股份 耗资约10亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2464869988","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464869988?lang=zh_cn&edition=full","pubTime":"2024-09-02 17:05","pubTimestamp":1725267941,"startTime":"0","endTime":"0","summary":"智通财经APP讯，凯莱英(002821.SZ)发布公告，截至2024年8月30日，公司累计通过回购专用证券账户以集中竞价方式回购公司股份数量为1230.07万股，占公司A股总股本的3.5976%，最高成交价为102.00元/股，最低成交价为71.65元/股，合计支付的总金额为10亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1178054.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1328615791.USD","002821","06821","BK0239","BK0132","BK1191"],"gpt_icon":0},{"id":"2464074395","title":"中邮证券：给予凯莱英买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2464074395","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464074395?lang=zh_cn&edition=full","pubTime":"2024-09-02 12:37","pubTimestamp":1725251831,"startTime":"0","endTime":"0","summary":"中邮证券有限责任公司近期对凯莱英进行研究并发布了研究报告《业务发展稳健，新签订单持续增长》，本报告对凯莱英给出买入评级，当前股价为61.92元。 盈利预测与投资建议 我们预计公司2024-2026年实现归母净利润分别为12.14/15.65/20.67亿元，对应EPS分别为3.30/4.26/5.62元，当前股价对应PE分别为19.28/14.96/11.33倍，首次覆盖，给予“买入”评级。最新盈利预测明细如下：该股最近90天内共有8家机构给出评级，买入评级8家；过去90天内机构目标均价为82.0。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090200011289.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","002821","06821"],"gpt_icon":0},{"id":"2463733134","title":"凯莱英：计划参加2024年度天津辖区上市公司半年报业绩说明会暨投资者网上集体接待日活动","url":"https://stock-news.laohu8.com/highlight/detail?id=2463733134","media":"金融界港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463733134?lang=zh_cn&edition=full","pubTime":"2024-08-30 18:16","pubTimestamp":1725012986,"startTime":"0","endTime":"0","summary":"金融界8月30日消息，凯莱英宣布将参加2024年度天津证监局、天津上市公司协会与深圳市全景网络有限公司联合举办的“天津辖区上市公司半年报业绩说明会暨投资者网上集体接待日活动”。此次活动将于2024年9月3日以网络远程的方式举行，会议期间，公司部分董事及高级管理人员将在线回答投资者关于公司发展战略、公司治理、经营状况、业绩及可持续发展等问题。\n\n\r\n 责任编辑：磐石","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/08/30181642916564.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["06821","BK0132","LU1328615791.USD","002821","BK0239","BK1191"],"gpt_icon":0},{"id":"2463214995","title":"凯莱英（002821）2024年中报简析：净利润减70.4%，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2463214995","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463214995?lang=zh_cn&edition=full","pubTime":"2024-08-30 06:20","pubTimestamp":1724970027,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期凯莱英发布2024年中报。截至本报告期末，公司营业总收入26.97亿元，同比下降41.63%，归母净利润4.99亿元，同比下降70.4%。本报告期凯莱英三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达68.21%。去年的净利率为28.76%，算上全部成本后，公司产品或服务的附加值高。重仓凯莱英的前十大基金见下表：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024083000006405.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002821","06821"],"gpt_icon":0},{"id":"2463213907","title":"民生证券：给予凯莱英买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2463213907","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463213907?lang=zh_cn&edition=full","pubTime":"2024-08-30 04:46","pubTimestamp":1724964371,"startTime":"0","endTime":"0","summary":"民生证券股份有限公司王班,乔波耀近期对凯莱英进行研究并发布了研究报告《2024年半年报点评：新签订单强劲增长，加速海外基地及多肽产能布局》，本报告对凯莱英给出买入评级，当前股价为62.93元。公司小分子CDMO业务上半年收入21.95亿元，剔除大订单影响后同比增长2.5%，毛利率达47.2%。最新盈利预测明细如下：该股最近90天内共有5家机构给出评级，买入评级5家；过去90天内机构目标均价为89.5。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024083000005085.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","002821","06821"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2016-11-18","address":"天津市滨海新区经济技术开发区洞庭三街6号","stockEarnings":[{"period":"1week","weight":0.0018},{"period":"1month","weight":-0.0501},{"period":"3month","weight":-0.0999},{"period":"6month","weight":-0.311},{"period":"1year","weight":-0.5393},{"period":"ytd","weight":-0.4445}],"companyName":"凯莱英医药集团(天津)股份有限公司","boardCode":"AI0027","perCapita":"--","boardName":"医药制造业","registeredCapital":"36771万元","compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":-0.061},{"period":"3month","weight":-0.0959},{"period":"6month","weight":-0.1085},{"period":"1year","weight":-0.1305},{"period":"ytd","weight":-0.0866}],"survey":" 凯莱英医药集团(天津)股份有限公司是一家全球领先的服务于新药研发和生产的CDMO一站式综合服务商。为国内外大中型制药企业、生物技术公司提供高效和高质量的研发与生产服务，助推创新药的临床研究与商业化应用。主要包括临床阶段药品、商业化阶段药品、技术服务。公司是全球第五大创新药原料药CDMO公司，约占据1.5%的市场份额（第一名市场份额约为2.9%）；是中国最大的商业化阶段化学药物CDMO公司，约占据22%的市场份额。","serverTime":1726733012905,"listedPrice":30.53,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.4","shortVersion":"4.26.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"凯莱英(002821)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供凯莱英(002821)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"凯莱英,002821,凯莱英股票,凯莱英股票老虎,凯莱英股票老虎国际,凯莱英行情,凯莱英股票行情,凯莱英股价,凯莱英股市,凯莱英股票价格,凯莱英股票交易,凯莱英股票购买,凯莱英股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"凯莱英(002821)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供凯莱英(002821)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}